Angélica Rocío Álvarez Mina

Bio: Angélica Rocío Álvarez Mina is an academic researcher. The author has an hindex of 1, co-authored 1 publications receiving 1 citations.

Hemofilia B o enfermedad de Christmas

Abstract: La hemofilia B o enfermedad de Christmas se diferencio por primera vez de la hemofilia A en 1947. Su forma clasica consiste en un trastorno hereditario de la coagulacion causado por mutaciones en el gen F9, que codifica para el factor IX de la coagulacion. Su herencia esta ligada al cromosoma X; las mujeres son portadoras, pero se manifiesta clinicamente en hombres, aunque se han descrito casos de mujeres portadoras sintomaticas. El factor IX activado es una proteina dependiente de vitamina K, sintetizada en el higado, que forma parte del complejo tenasa, cuya funcion es formar la mayor cantidad de trombina en el nuevo modelo de la coagulacion basado en celulas. De acuerdo a la actividad del factor IX, su deficiencia se puede clasificar en leve (5% a 40%), moderada (1% a 5%), o severa (<1%). Su diagnostico se realiza con la presencia de un TPT alargado que corrige con plasma normal y con la determinacion del nivel funcional del factor IX, y se confirma con el estudio molecular que demuestra la mutacion en el gen F9. Su diagnostico diferencial incluye otras patologias como la hemofilia A. El tratamiento con factor IX recombinante es el mas utilizado en la actualidad, pero se vienen desarrollando nuevas terapias con virus adeno-asociados recombinantes que prometen mejorar la calidad de vida para algunos pacientes afectados. La profilaxis juega un papel fundamental, en particular en los casos de enfermedad moderada y severa

Hemofilia A: una enfermedad huérfana

Abstract: Hemophilia A is an X-linked inherited disease caused by mutations in the coagulation factor VIII F8 gene. It is considered a rare disease, as its prevalence is 26.6 per 100,000 live male births. Patients with hemophilia A have a relatively normal coagulation onset and amplification phases, and are able to form the initial platelet plug at the site of hemorrhage; but due to factor VIII deficiency, they are unable to generate a sufficient amount of thrombin on the platelet surface to stabilize the fibrin clot. In a male patient with unusual bleeding, a hemophilia A-type coagulation disorder should be ruled out, and blood tests such as a platelet count and prothrombin time (PT), which are usually normal, and an activated partial thromboplastin time (APTT), which is prolonged, should be requested immediately. For differential diagnosis with other coagulopathies, measurement of coagulation factors and correction tests are performed when there is suspicion of an inhibitor or acquired hemophilia. Affected patients may present mild, moderate or severe forms of the disease, depending on the plasma level of the factor. In Colombia and worldwide, hemophilia was recognized as a rare disease that represents a public health problem due to its highly specialized care, which increases the costs associated with health care, and affects the quality of life of patients and those around them, as well as representing a diagnostic challenge that requires constant updating, so that it can be treated effectively.